New Frontiers of HCV Therapy in HIV/HCV Co-infection

Amorosa, Valerianna

doi:10.1007/s11904-010-0051-7

Search citation statements

Order By: Relevance

Paper Sections

Select...

Potential Cocktail Components1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2011

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[39] Compounds tested as part of IFN-free regimens in phase 2 trials include the nucleoside analogue RG7128[38] and the non-nucleoside VCH-222 (renamed VX-222 with the purchase of Virochem by Vertex). [40]…”

Section: Potential Cocktail Componentsmentioning

confidence: 99%

Mixing the right hepatitis C inhibitor cocktail

Gelman

Glenn

2011

Trends in Molecular Medicine

View full text Add to dashboard Cite

Therapy for hepatitis C virus (HCV) infection is on the cusp of a new era. Until now, standard of care (SOC) therapy has involved interferon (IFN) and ribavirin. With the first successful phase 3 trials of specific targeted antiviral therapy for HCV (STAT-C) compounds, as well as three trials in progress giving the first glimpse of IFN-free combinations of STAT-C agents, this review looks ahead to the new classes of anti-HCV agents currently in clinical development. Successful pharmacologic control of HIV and TB frames the discussion, as well as consideration of the mutation frequency of HCV replication. Maximizing synergy between agents and minimizing cumulative toxicity will be critical to the design of future IFN-free STAT-C regimens.

show abstract

Section: Potential Cocktail Componentsmentioning

confidence: 99%